Earnings Feed
Start Free
Home/Filings/4/0001782078-26-000002
4//SEC Filing

Cambre Jerome 4

Accession 0001782078-26-000002

CIK 0001729149other
View on SEC.govCompany Profile

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 5:02 PM ET

Size

18.8 KB

Accession

0001782078-26-000002

Research Summary

AI-generated summary of this filing

Updated

Viemed (VMD) VP Jerome Cambre Exercises Derivatives, Receives Awards

What Happened
Jerome Cambre, Vice President of Sales at Viemed Healthcare (VMD), had vested derivative awards settle on Jan 17, 2026 and received new awards on Jan 19, 2026. On Jan 17 he exercised/converted vested phantom share units and RSUs (from a Jan 17, 2023 grant), resulting in the acquisition/settlement of shares. A total of 4,916 shares were immediately surrendered/withheld: 2,784 shares were withheld to satisfy tax obligations (value $20,407) and 2,132 shares were surrendered to the issuer for cash settlement (value $15,628) — total cash value ≈ $36,035. On Jan 19 he was granted 40,676 phantom shares (cash-settled equivalents) and 10,169 RSUs; both awards vest in three equal annual installments beginning on the first anniversary of the grant.

Key Details

  • Transaction dates: Jan 17, 2026 (vesting/settlement) and Jan 19, 2026 (new grants). Filing date: Jan 21, 2026.
  • Identified dispositions: 2,784 shares withheld for taxes @ $7.33 = $20,407; 2,132 shares surrendered to issuer @ $7.33 = $15,628. Total disposed ≈ 4,916 shares / $36,035.
  • New awards: 40,676 phantom shares (cash-settled) and 10,169 RSUs granted Jan 19, 2026 (vest in 3 equal annual installments).
  • Footnotes: F2 = tax-withheld RSUs; F4 & F8 = phantom shares are cash-settled equivalents of common shares; F5–F6 = the Jan 17, 2023 awards vested in installments; F7–F9 = the Jan 19, 2026 awards vest over three years.
  • Shares owned after the transactions are not specified in the provided filing.
  • No late-filing flag was provided in the materials reviewed.

Context

  • The Jan 17 activity appears to be routine vesting/cash settlement of previously granted RSUs and phantom shares, not an open-market sale or purchase. The withheld/surrendered shares were used to cover withholding taxes and cash settlement obligations (common for vested equity awards).
  • The Jan 19 entries are new equity grants (RSUs and phantom units) that will vest over time; these are awards rather than purchases and do not by themselves signal buying or selling preference.

Insider Transaction Report

Form 4
Period: 2026-01-17
VIEMED HEALTHCARE, INC.VMD
Cambre Jerome
Vice President of Sales
Transactions
  • Exercise/Conversion

    Common Shares

    [F1]
    2026-01-17+8,525→ 92,716 total
  • Tax Payment

    Common Shares

    [F2][F3]
    2026-01-17$7.33/sh−2,784$20,407→ 89,932 total
  • Exercise/Conversion

    Common Shares

    [F4]
    2026-01-17+2,132→ 92,064 total
  • Disposition to Issuer

    Common Shares

    [F3]
    2026-01-17$7.33/sh−2,132$15,628→ 89,932 total
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F5]
    2026-01-17−8,525→ 0 total
    Exp: 2026-01-17→ Common Shares (8,525 underlying)
  • Exercise/Conversion

    Phantom Share Units

    [F4][F6]
    2026-01-17−2,132→ 0 total
    Exp: 2026-01-17→ Common Shares (2,132 underlying)
  • Award

    Restricted Stock Units

    [F1][F7]
    2026-01-19+40,676→ 40,676 total
    Exp: 2029-01-19→ Common Shares (40,676 underlying)
  • Award

    Phantom Share Units

    [F8][F9]
    2026-01-19+10,169→ 10,169 total
    Exp: 2029-01-19→ Common Shares (10,169 underlying)
Footnotes (9)
  • [F1]Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.
  • [F2]Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.
  • [F3]Per share value is based on the market closing price of the common shares for January 16, 2026.
  • [F4]Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.
  • [F5]Restricted Stock Units (RSUs) granted to reporting person on January 17, 2023, which vest in three equal annual installments beginning on the first anniversary of the grant date.
  • [F6]Represents an award granted on January 17, 2023 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.
  • [F7]Restricted Stock Units (RSUs) granted to reporting person on January 19, 2026, which vest in three equal annual installments beginning on the first anniversary of the grant date.
  • [F8]Each phantom share represents a right to receive the cash value of one share of the Issuer's common shares which will be determined based on the Issuer's share price on the vesting date.
  • [F9]Represents an award granted on January 19, 2026 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.
Signature
/s/ Jesse Bergeron, Attorney-in-Fact|2026-01-21

Documents

1 file

Issuer

VIEMED HEALTHCARE, INC.

CIK 0001729149

→
Entity typeother

Related Parties

1
  • filerCIK 0001782078

Filing Metadata

Form type
4
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 5:02 PM ET
Size
18.8 KB
View on SEC.gov